Clinical Evaluation of Shufeng Jiedu Capsules Combined with Umifenovir (Arbidol) in the Treatment of Common-type COVID-19: a Retrospective Study

Overview

Journal Expert Rev Respir Med

Specialty Pulmonary Medicine

Date 2020 Sep 17

PMID 32941741

Citations 24

Authors

Jing Chen

Shaowu Lin

Conway Niu

Qi Xiao

Affiliations

Soon will be listed here.

Abstract

Objective: To understand the clinical effectiveness and safety of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19.

Methods: A retrospective cohort study was used to analyze the case data of 200 inpatients diagnosed with common-type COVID-19 at Wuhan Hospital. Participants were divided into a control group and an experimental group. The control group was treated with Arbidol hydrochloride capsules while the experimental group was treated with combination Arbidol hydrochloride capsules and Shufeng Jiedu Capsules (SFJDC) for 14 days.

Results: Defervescence was achieved more rapidly in the experimental group ( < 0.05). The white blood cell count and the lymphocyte percentage in the experimental group were higher than that of the control group ( < 0.05). CRP and IL-6 levels in the experimental group were significantly lower than those in the control group ( < 0.05). The proportion of chest CT studies showing resolution of pneumonia in the experimental group was significantly higher than that in the control group ( < 0.05).

Conclusions: A treatment regimen of Shufeng Jiedu Capsules combined with Arbidol to treat common-type COVID-19, combining traditional Chinese and western allopathic medicine, improves time to recovery, has better clinical effectiveness, and is safe.

Citing Articles

Mechanisms of Shufeng Jiedu Capsule in treating bacterial pneumonia based on network pharmacology and experimental verification.

Xu Y, Bao L, Zhao R, Geng Z, Li S, Pang B Chin Herb Med. 2024; 16(4):656-666.

PMID: 39606267 PMC: 11589334. DOI: 10.1016/j.chmed.2024.01.002.

Effectiveness of seven oral traditional Chinese medicines against mild or moderate COVID-19: An updated systematic review and network meta-analysis.

Zhang T, Li T, Zhao F, Li T, Zhang M, Jin P Heliyon. 2024; 10(15):e35081.

PMID: 39170141 PMC: 11336365. DOI: 10.1016/j.heliyon.2024.e35081.

Shufeng Jiedu capsule alleviates influenza A (H1N1) virus induced acute lung injury by regulating the lung inflammatory microenvironment.

Wang X, Geng Z, Bao Y, Zhong J, Ma J, Cui X Heliyon. 2024; 10(12):e33237.

PMID: 39021925 PMC: 11252743. DOI: 10.1016/j.heliyon.2024.e33237.

Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.

Lu C, Yang L, Jin X, Friedemann T, Li Y, Liu X Front Pharmacol. 2024; 15:1383831.

PMID: 38863976 PMC: 11165997. DOI: 10.3389/fphar.2024.1383831.

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies.

Kumawat P, Agarwal L, Sharma K Curr Microbiol. 2024; 81(7):169.

PMID: 38733424 DOI: 10.1007/s00284-024-03671-3.

References

Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

Wang Y, Ding Y, Yang C, Li R, Du Q, Hao Y . Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret). Biomed Pharmacother. 2017; 91:393-401. DOI: 10.1016/j.biopha.2017.04.091. View

Zaki A, van Boheemen S, Bestebroer T, Osterhaus A, Fouchier R . Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367(19):1814-20. DOI: 10.1056/NEJMoa1211721. View

Lu H . Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020; 14(1):69-71. DOI: 10.5582/bst.2020.01020. View

Perlman S . Another Decade, Another Coronavirus. N Engl J Med. 2020; 382(8):760-762. PMC: 7121143. DOI: 10.1056/NEJMe2001126. View

Lim J, Jeon S, Shin H, Kim M, Seong Y, Lee W . Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020; 35(6):e79. PMC: 7025910. DOI: 10.3346/jkms.2020.35.e79. View

Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View

10.

Silva M, Bercik P . Macrophages are related to goblet cell hyperplasia and induce MUC5B but not MUC5AC in human bronchus epithelial cells. Lab Invest. 2012; 92(6):937-48. DOI: 10.1038/labinvest.2012.15. View

11.

Yuan Y, Liao Q, Xue M, Shi Y, Rong L, Song Z . Shufeng Jiedu Capsules Alleviate Lipopolysaccharide-Induced Acute Lung Inflammatory Injury via Activation of GPR18 by Verbenalin. Cell Physiol Biochem. 2018; 50(2):629-639. DOI: 10.1159/000494184. View

12.

Health Commission Of The Peoples Republic Of China N . Protocol for Prevention and Control of COVID-19 (Edition 6). China CDC Wkly. 2021; 2(19):321-326. PMC: 8392946. DOI: 10.46234/ccdcw2020.082. View

13.

Tao Z, Yang Y, Shi W, Xue M, Yang W, Song Z . Complementary and alternative medicine is expected to make greater contribution in controlling the prevalence of influenza. Biosci Trends. 2013; 7(5):253-6. View

14.

Wang Z, Chen X, Lu Y, Chen F, Zhang W . Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020; 14(1):64-68. DOI: 10.5582/bst.2020.01030. View

15.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

16.

Pan M, Chiou Y, Tsai M, Ho C . Anti-inflammatory activity of traditional Chinese medicinal herbs. J Tradit Complement Med. 2014; 1(1):8-24. PMC: 3943005. DOI: 10.1016/s2225-4110(16)30052-9. View

17.

Ainsworth D, Reyner C . Effects of in vitro exposure to autologous blood and serum on expression of interleukin-8, interleukin-1β, and chemokine (C-X-C motif) ligand 2 in equine primary bronchial epithelial cell cultures. Am J Vet Res. 2012; 73(2):296-301. DOI: 10.2460/ajvr.73.2.296. View

18.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

19.

Wang Q, Kuang H, Su Y, Sun Y, Feng J, Guo R . Naturally derived anti-inflammatory compounds from Chinese medicinal plants. J Ethnopharmacol. 2013; 146(1):9-39. DOI: 10.1016/j.jep.2012.12.013. View